Skip to main content
Clinical Trials/NCT03013868
NCT03013868
Unknown
Not Applicable

CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System

MiCareo Taiwan Co., Ltd.1 site in 1 country200 target enrollmentOctober 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Circulating Tumor Cells, CTC
Sponsor
MiCareo Taiwan Co., Ltd.
Enrollment
200
Locations
1
Primary Endpoint
Disease Free Survival
Last Updated
7 years ago

Overview

Brief Summary

Despite the growing public awareness and recent progress in multimodality therapy to the colorectal cancer (CRC), CRC still ranks high on the list of the most common and deadly cancers in Taiwan. The cause of CRC mortality is due mainly to the occurrence of distant metastasis. Several reports suggested that circulating tumor cells (CTCs) highly associated with metastasis suggesting that targeting CTCs may offer an unprecedented opportunity to prevent the development of metastasis. Early detection and characterization of CTCs is therefore important as a potential strategy to monitor the progression of CRC. The current proposal is focused on detecting CTCs from peripheral blood of CRC patients using Miselect R system. We will monitor the amount of CTCs and correlate with CRC progression and prognosis.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
February 2021
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Over 20 and less than 90 years of age.
  • Colorectal cancer stage II/III patients who will undergo surgical resection.
  • Subject having agreed to participate in the study and follow the study procedures by providing written informed consent prior entering the study.

Exclusion Criteria

  • Have other cancer history.
  • Subject being identified with any blood borne infectious disease

Outcomes

Primary Outcomes

Disease Free Survival

Time Frame: 5 years

Study Sites (1)

Loading locations...

Similar Trials